Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for investment professionals · Tuesday, April 16, 2024 · 704,206,988 Articles · 3+ Million Readers

SEC ORDERS SUSPENSION IN TRADING OF INSTADOSE PHARMA SECURITIES - Kehoe Law Firm, P.C. Class Action Investigation

Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C.

Instadose Pharma Investors Who Have Suffered Losses Encouraged To Contact Kehoe Law Firm, P.C.

PHILADELPHIA, PA, USA, November 26, 2021 /EINPresswire.com/ -- Kehoe Law Firm, P.C. is investigating whether Instadose Pharma Corp. (“Instadose Pharma” or the “Company”) (OTC: INSD) violated federal securities laws.

Instadose Pharma's recently filed Form 8-K reported that “[o]n November 23, 2021, the Company was notified by the SEC that it had ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the . . . Company is suspended for the period from 9:30 a.m. EDT on November 24, 2021, through 11:59 p.m. EDT on December 8, 2021.”

Instadose Pharma reported that “[t]he [SEC’s] Order stated that it appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Instadose Pharma . . . because of questions and concerns regarding the adequacy and accuracy of information about Instadose Pharma in the marketplace, including: (1) significant increases in the stock price and share volume unsupported by the company’s assets and financial information; (2) trading that may be associated with individuals related to a control person of Instadose Pharma; and(3) the operations of Instadose Pharma’s Canadian affiliate. . . .”

The stock price of Instadose Pharma dropped more than 13% during intraday trading on November 23, 2021.

INSTADOSE PHARMA INVESTORS WHO HAVE LOST MONEY ARE ENCOURAGED TO CONTACT EITHER JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, JKEHOE@KEHOELAWFIRM.COM, OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO DISCUSS THE INSTADOSE PHARMA SECURITIES CLASS INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.

John Kehoe, Esq.
Kehoe Law Firm, P.C.
2157926676, EXT. 801
jkehoe@kehoelawfirm.com

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release